Graduate
David Ure and David Arslanian, MBA’06, founded Inanovate in 2006. Inanovate sells a platform technology that enables the measurement of multiple biomarkers from blood samples in one low-cost test. Biomarkers, which are genes, proteins, or other biological molecules, are related to a specific disease, infection, or environmental exposure. A new generation of the company’s platform, Bio-ID800, is being launched later this year to support clinical trials for a low-cost monitoring test for breast cancer recurrence.